Breton E, Bridoux-Henno L, Guyader D, Daniélou H, Jouan H, Beuchée A, Nousbaum J B, Dabadie A
Unité des nourrissons et explorations fonctionnelles digestives, pôle médicochirurgical de pédiatrie et de génétique clinique, CHU de Rennes, 16, boulevard de Bulgarie, BP 90347, 35203 Rennes cedex 2, France.
Arch Pediatr. 2009 Jul;16(7):1005-10. doi: 10.1016/j.arcped.2009.03.021. Epub 2009 May 14.
Transient elastography (FibroScan) is a novel, noninvasive, rapid bedside method to assess liver fibrosis by measuring liver stiffness. This study aimed to determine the feasibility and reliability of liver stiffness measurement in children with liver diseases.
Liver stiffness measurements were carried out on 72 children, from 4 to 18 years of age, with potential hepatic fibrosis disease. The clinical, biological, ultrasonographic, and endoscopic parameters were noted to identify children with portal hypertension syndrome. The APRI (ASAT-to-platelet ratio index) test was calculated according to the standard formula. An APRI test score higher than 1.5 indicates significant hepatic fibrosis. METAVIR scoring from 14 liver biopsies was compared to the liver stiffness using the Kappa statistic.
Twenty-eight patients had viral hepatitis, 20 cystic fibrosis, 16 chronic liver cholestasis, 5 autoimmune hepatitis, and 3 patients had liver fibrosis with uncertain etiology. FibroScan measurements were available in all children. There was good agreement between FibroScan and pathological studies (weighted kappa=0.814). Only 9 children had portal hypertension syndrome with an average measurement of liver stiffness significantly higher than children without portal hypertension (26.5kPa vs 6.4kPa; p<0.01). The APRI test for 6 out of 9 patients scored higher than 1.5.
These results indicate that liver stiffness measurement is feasible in children and seems to be related to liver fibrosis. Larger prospective studies are needed to validate this FibroScan method.
瞬时弹性成像(FibroScan)是一种通过测量肝脏硬度来评估肝纤维化的新型、非侵入性、快速床边检测方法。本研究旨在确定在患有肝脏疾病的儿童中进行肝脏硬度测量的可行性和可靠性。
对72名年龄在4至18岁之间、患有潜在肝纤维化疾病的儿童进行肝脏硬度测量。记录临床、生物学、超声和内镜参数,以识别患有门静脉高压综合征的儿童。根据标准公式计算APRI(谷草转氨酶与血小板比值指数)测试值。APRI测试分数高于1.5表明存在显著肝纤维化。使用Kappa统计量将14例肝活检的METAVIR评分与肝脏硬度进行比较。
28例患者患有病毒性肝炎,20例患有囊性纤维化,16例患有慢性肝内胆汁淤积,5例患有自身免疫性肝炎,3例患者肝纤维化病因不明。所有儿童均获得了FibroScan测量结果。FibroScan与病理研究之间具有良好的一致性(加权kappa = 0.814)。只有9名儿童患有门静脉高压综合征,其肝脏硬度平均测量值显著高于无门静脉高压的儿童(26.5kPa对6.4kPa;p<0.01)。9例患者中有6例的APRI测试分数高于1.5。
这些结果表明,肝脏硬度测量在儿童中是可行的,并且似乎与肝纤维化有关。需要更大规模的前瞻性研究来验证这种FibroScan方法。